June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Retinal Vessel Caliber as a Predictor of Visual Outcome in Eyes with Diabetic Macular Edema (DME) Treated with Ranibizumab
Ahmadreza Moradi; Raafay Sophie; Rachel Annam; Owhofasa Agbedia; Hongting Liu; Mostafa Hanout; Millena Bittencourt; Mohamed Ibrahim; Diana Do; Quan Dong Nguyen
Author Affiliations & Notes
  • Ahmadreza Moradi
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Raafay Sophie
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Rachel Annam
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Owhofasa Agbedia
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Hongting Liu
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Mostafa Hanout
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Millena Bittencourt
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Mohamed Ibrahim
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Diana Do
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Quan Dong Nguyen
    Retinal Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Footnotes
    Commercial Relationships Ahmadreza Moradi, None; Raafay Sophie, None; Rachel Annam, None; Owhofasa Agbedia, None; Hongting Liu, None; Mostafa Hanout, None; Millena Bittencourt, None; Mohamed Ibrahim, None; Diana Do, Genentech (F), Regeneron (F); Quan Dong Nguyen, Genentech (F), Regeneron (F), Lux Biosciences (F), Abbott (F), GSK (F), Santen (F), Santen (C), Bausch and Lomb (C), Optos (F), Heidelberg Engineering (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 21. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Retinal Vessel Caliber as a Predictor of Visual Outcome in Eyes with Diabetic Macular Edema (DME) Treated with Ranibizumab
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Ahmadreza Moradi, Raafay Sophie, Rachel Annam, Owhofasa Agbedia, Hongting Liu, Mostafa Hanout, Millena Bittencourt, Mohamed Ibrahim, Diana Do, Quan Dong Nguyen; Retinal Vessel Caliber as a Predictor of Visual Outcome in Eyes with Diabetic Macular Edema (DME) Treated with Ranibizumab. Invest. Ophthalmol. Vis. Sci. 2013;54(15):21.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: It has been reported that baseline venular caliber may be associated with visual outcomes in eyes with neovascular AMD treated with ranibizumab (RBZ) (Wickremasinghe et al. 2012). The index study aims to identify whether baseline retinal vessel caliber predicts visual outcome of patients with diabetic macular edema (DME) treated with RBZ.

Methods: The 1M field (as defined in the ETDRS study) of digital color fundus photographs of DME patients treated primarily with RBZ in a clinical trial were assessed. At baseline, the average retinal vascular caliber of the 6 largest venules (CRVE) and the 6 largest arterioles (CRAE) in the peripapillary area (0.5 and 1 disc diameter from the optic disc margin) was measured and analyzed using Interactive Vessel ANalysis (IVAN) software version 1.30 (Knudtson et al, 2003). The relationship of CRVE and CRAE at baseline to the change in visual acuity at months 12 was assessed using the Mann Whitney U test.

Results: Twenty-five eyes which met all study criteria were analyzed. Ten eyes of 10 patients who had an improvement of ≥2 lines of best corrected visual acuity (BCVA) at months 12 had wider baseline CRVE (248.3±24.5µm) compared to 15 eyes of 15 patients who did not have an improvement of ≥2 lines (226.6±44.8µm, P<0.05). Baseline CRAE did not differ significantly in these patients (156.1±22.7 µm versus 142±17.5µm, p=0.17). Mean BCVA at baseline was 26.5 and 25.6 letters (those who gained ≥2 and < 2 lines, respectively). Systemic mean arterial pressures (MAPs) were also analyzed for all patients and were found to be balanced between the two groups.

Conclusions: A wider baseline retinal venular caliber may be a predictor of better visual outcome in DME patients treated with RBZ. Further prospective studies with a larger number of eyes are needed to confirm our findings.

Keywords: 499 diabetic retinopathy • 505 edema • 503 drug toxicity/drug effects  
© 2013, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept